Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy

NCT06680622 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

126

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Gastro-esophageal Adenocarcinoma

Interventions

DRUG: bemarituzumab, paclitaxel, ramucirumab
DRUG: bemarituzumab, irinotecan
DRUG: bemarituzumab, trifluridine/tipiracil

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborators

[object Object]
[object Object]
[object Object]